These findings supported the notion that Gal-3 regulates K-Ras protein localization into the plasma membrane

These findings supported the notion that Gal-3 regulates K-Ras protein localization into the plasma membrane. MEFs. Furthermore, phosphorylation of Gal-3 by casein kinase-1 (CK-1) induced translocation of Gal-3 from FLJ39827 the nucleus to the cytoplasm and the plasma membrane, leading to K-Ras stabilization accompanied by downregulation of the tumor suppressor miRNA let-7c, known to negatively control K-Ras transcription. == Conclusions == Our results suggest a novel cross-talk between Gal-3-mediated downregulation of let 7c microRNA (which in turn negatively regulates K-Ras transcription) and elucidates the association among ALW-II-41-27 Gal-3 let-7c and K-Ras transcription/translation, cellular compartmentalization and activity. == Introduction == MicroRNAs (miRNAs) are small, noncoding RNAs that regulate gene expression by repressing transcription or degradation of the target ALW-II-41-27 mRNA[1]. In cancer cells, miRNAs can regulate tumor development by functioning as tumor suppressors or as oncogenes[2]. Ras genes and oncogenes are regulated by members of the let-7 miRNA family by virtue of the possession by these genes oflet-7complementary sites in their 3-untranslated regions (UTRs)[3]. Reduction of let-7 has been reported in several human cancers including melanoma, colon and lung[4][6]and their expression has been shown to attenuate cancer cell proliferation and tumorigenicity[7],[8]. Recently a single-nucleotide polymorphism (SNP) was detected in alet-7miRNA complementary site in theKRAS3UTR in non-small cell lung carcinoma (NSCLC) and was found to be correlated with increased risk for NSCLC[9]. In normal cells, let-7 miRNAs act as tumor-suppressor genes that downregulate Ras expression[2]. Here we examined the possibility that Galectin-3 (Gal-3) interacts with active K-Ras[10],[11]and may modulate let-7 expression. Gal-3 is a -galactoside-binding protein that contains a COOH-terminal carbohydrate recognition/binding domain and an NH2-terminal proline- and glycine-rich domain[12]. Gal-3 is highly expressed in a number of human malignances and has been shown to stimulate cellular proliferation, anchorage-independent cell growth, and inhibition of apoptosis via K-Ras-mediated Raf/MEK/ERK activation[10]. K-Rasis the most frequently mutated of the Ras genes (H-, N- andK-Ras)in human cancers[13],[14]. The proteins encoded by Ras genes are key players in development and in carcinogenic processes and tumor maintenance. They are guanine nucleotide-binding proteins that act as binary molecular switches around the inner plasma membrane and on intracellular membranes. In response to activation by growth-factor receptors, Ras proteins are activated by guanine nucleotide exchange factors (GEFs) that stimulate GDP/GTP exchange. Ras guanine nucleotide-activating proteins (RasGAPs) contribute to GTP hydrolysis by Ras. In the active (GTP-bound) state, Ras proteins recruit downstream effectors from the cytosol to the plasma membrane for activation. They activate a multitude of effectors including Raf, phosphatidylinositol-3-OH kinase (PI3-K), and Ral-GEFs, which together regulate cell proliferation, differentiation, survival, and death. Oncogenic Ras proteins are insensitive to RasGAPs ALW-II-41-27 and are therefore constitutively active[15][17]. We have previously shown that K-Ras gains some of its important oncogenic properties by interaction with Gal-3, which acts as a selective intracellular scaffold of K-Ras.GTP[10],[11]. Such interaction stabilizes K-Ras in its active (GTP-bound) state as if it is constitutively active ALW-II-41-27 oncogenic K-Ras[10],[11]. It also strengthens the binding of K-Ras.GTP to the cell membrane, increases its nanoclustering in the membrane, and enhances its robust signaling[18]. Other groups as well as ours have found a close correlation between Gal-3 expression, malignancy, tumorigenicity and K-Ras.GTP, specifically; high cellular Gal-3 protein expression results in K-Ras GTP loading[19], and for this interaction to occur, Gal-3 must be translocated from the nucleus to the cytoplasm[20]. The Gal-3 translocation is regulated by its phosphorylation catalyzed by casein kinase 1 (CK1)[21],[22]. This phosphorylation promotes the nucleus-to-cytosol translocation[20]and hence the retention/stability of K-Ras.GTP in the plasma membrane. Loss of nuclear Gal-3 expression is associated with tumor progression[20], just as loss of let-7 leads to progression of many human tumors[23]. These findings led us to postulate that loss of Gal-3 might be related to the increase in let-7 and decrease in K-Ras stability. Here we used Gal-3-knockout mouse embryonic fibroblasts (MEFs) and CK1 inhibitors to demonstrate a newly identified dual regulatory mode of K-Ras. The results indicate that Gal-3 negatively regulates let-7 expression, which in turn leads to increased expression of K-Ras. We further report that Gal-3 phosphorylation is regulated by CK1, which stabilizes the membrane activity of activated K-Ras protein. == Materials and Methods == == Transgenic Gal-1-Knockout (Gal-1-/-), Gal-3-Knockout (Gal-3-/-) and Gal-1/Gal-3 Double-Knockout (Gal-1-/-/Gal-3-/-) Mice.